InvestorsHub Logo
Followers 27
Posts 4793
Boards Moderated 0
Alias Born 04/30/2005

Re: None

Thursday, 06/30/2022 4:22:09 PM

Thursday, June 30, 2022 4:22:09 PM

Post# of 408117
Final thoughts- What he should have said:

Let me tell you about our new approval of the ANDA for Sabril a treatment for epilepsy. Our distribution partner has the EXCLUSIVE rights to sell the product in the US so that we may get a large portion of the market share when we complete the commercialization with Lannett. This is a relatively expensive medication which , of course, will provide a nice revenue boost. In 6 weeks I can give you a better update.
I would also like to mention that the drug is in two exciting clinical trials that will conclude in December. It is the first time we have gotten approval of a powder which we formulated in house.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News